科伦博泰生物-B高开逾5% 于2025 ESMO大会上公布佳泰莱 等多项临床研究成果

Core Viewpoint - Kolon Biotech Inc. (06990) experienced a significant increase in stock price, rising by 5.37% to HKD 483, with a trading volume of HKD 1.5939 million, following the announcement of multiple clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference held in Berlin from October 17 to 21 [1]. Group 1 - Kolon Biotech announced the presentation of several clinical research results at the ESMO conference [1]. - The research included data on targeted antibody-drug conjugates (ADCs) such as sac-TMT (佳泰莱), A166 (舒泰莱), and SKB315 [1]. - The focus of the studies was on TROP2, HER2, and Claudin18.2 [1].